Attovia Therapeutics, Inc. (ATTO)Healthcare | Biotechnology | San Carlos, United States | NasdaqGM
20.70 USD
-0.76
(-3.541%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 20.70 |
Hot Take ↕ | Aug. 22, 2026, 4:19 a.m. EDT
The immediate outlook is severely clouded by a brutal recent price collapse. Despite a brief, sharp recovery late last week, the stock has shed significant value over the past fortnight, trading well below its 50-day moving average. This technical weakness suggests continued selling pressure in the near term. Looking further ahead, the investment case is fundamentally broken. The company operates in biotechnology with zero revenue, massive negative operating margins, and a negative book value, indicating the market price exceeds the liquidation value of assets. Crucially, the price history reveals a multi-year structural decline where the asset is lower today than at the start of the observation window, confirming a deteriorating business trajectory rather than a temporary setback. With no dividends paid and no analyst coverage, there is no safety net for investors. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.62 |
| Revenue per Share | 0.334 |
| Market Cap | 890,700,672 |
| Website | https://www.attovia.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.05479455 |
| Address1 | 1,091 Industrial Road |
| Address2 | Suite 310 |
| All Time High | 24.32 |
| All Time Low | 16.15 |
| Average Daily Volume10 Day | 217,990 |
| Average Daily Volume3 Month | 538,838 |
| Average Volume | 538,838 |
| Average Volume10Days | 217,990 |
| Book Value | -27.824 |
| City | San Carlos |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 20.7 |
| Current Ratio | 13.944 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 21.54 |
| Day Low | 20.02 |
| Debt To Equity | 3.62 |
| Display Name | Attovia Therapeutics |
| Ebitda | -70,107,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.192 |
| Enterprise To Revenue | 165.768 |
| Enterprise Value | 223,787,216 |
| Eps Trailing Twelve Months | -2.5 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 20.487778 |
| Fifty Day Average Change | 0.21222305 |
| Fifty Day Average Change Percent | 0.01035852 |
| Fifty Two Week Change Percent | -5.479455 |
| Fifty Two Week High | 24.32 |
| Fifty Two Week High Change | -3.619999 |
| Fifty Two Week High Change Percent | -0.14884864 |
| Fifty Two Week Low | 16.15 |
| Fifty Two Week Low Change | 4.550001 |
| Fifty Two Week Low Change Percent | 0.2817338 |
| Fifty Two Week Range | 16.15 - 24.32 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,785,936,600,000 |
| Float Shares | 2,478,293 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 44 |
| Fullday Change | -0.759998 |
| Fullday Change Percent | -3.54146 |
| Fullday Price | 20.7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -57,608,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23696 |
| Held Percent Institutions | 0.47616002 |
| Implied Shares Outstanding | 43,029,017 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-08-05 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California. |
| Long Name | Attovia Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 890,700,672 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1844489898 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -64,132,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Open | 21.37 |
| Operating Cashflow | -63,209,000 |
| Operating Margins | -52.6 |
| Payout Ratio | 0.0 |
| Phone | 510 399 5001 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 20.7 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 21.46 |
| Price Hint | 2 |
| Price To Book | -0.7439621 |
| Price To Sales Trailing12 Months | 659.77826 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.606 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.759998 |
| Regular Market Change Percent | -3.54146 |
| Regular Market Day High | 21.54 |
| Regular Market Day Low | 20.02 |
| Regular Market Day Range | 20.02 - 21.54 |
| Regular Market Open | 21.37 |
| Regular Market Previous Close | 21.46 |
| Regular Market Price | 20.7 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 127,603 |
| Revenue Per Share | 0.334 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 43,029,017 |
| Shares Short | 511,865 |
| Short Name | Attovia Therapeutics, Inc. |
| Short Ratio | 0.54 |
| Source Interval | 15 |
| State | CA |
| Symbol | ATTO |
| Total Cash | 132,622,000 |
| Total Cash Per Share | 29.399 |
| Total Debt | 4,804,000 |
| Total Revenue | 1,350,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.5 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.487778 |
| Two Hundred Day Average Change | 0.21222305 |
| Two Hundred Day Average Change Percent | 0.01035852 |
| Type Disp | Equity |
| Volume | 127,603 |
| Website | https://www.attovia.com |
| Zip | 94,070 |